Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds
- Details
- Category: Takeda
H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeckâ's pipeline for the treatment of mood and anxiety disorders.
ERS COPD Research Awards 2007 Sponsored by Boehringer Ingelheim
- Details
- Category: Boehringer Ingelheim
The European Respiratory Society (ERS) is pleased to announce that Dr Morten Dahl, Herlev University Hospital in Copenhagen, Denmark and Simonetta Baraldo, Padova, Italy, are this year's winners of the Society's annual award for research in the field of Chronic Obstructive Pulmonary Disease (COPD).
Invega® receives marketing authorisation in European Union for treatment of schizophrenia
- Details
- Category: Product
The European Commission, on 25 June 2007, granted marketing authorisation for INVEGA® (paliperidone prolonged-release tablets), a new atypical antipsychotic medication for the treatment of schizophrenia. This once daily medication is specifically designed to deliver paliperidone - the active ingredient in INVEGA® - through the innovative osmotic delivery system (OROS®) resulting in strong efficacy, a proven safety and tolerability profile and improved patient functioning.
Novartis completes agreement with Bayer Schering related to Betaseron®
- Details
- Category: Novartis
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron®[1] (interferon beta-1b) and has received a one-time payment of approximately USD 200 million.
FDA Accepts NDA Filing for Cleviprex(TM) for the Treatment of Acute Hypertension
- Details
- Category: Product
The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's new drug application (NDA) for Cleviprex(TM) (clevidipine butyrate injectable emulsion) for the treatment of acute hypertension. If approved, Cleviprex will be the first new treatment for acute hypertension in more than 10 years.
Merck & Co., Inc. Announces Completion of NovaCardia, Inc. Acquisition
- Details
- Category: Merck
Merck & Co., Inc. announced that it has successfully completed the acquisition of NovaCardia, Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. This acquisition adds rolofylline (KW-3902), NovaCardia's investigational Phase III compound for acute heart failure to Merck's pipeline.
FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
- Details
- Category: Bayer
Today, the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol® (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.
More Pharma News ...
- Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits
- Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib
- ERBITUX® Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- PLIVA Enters Oncology Business in Germany
- Novo Nordisk is Rated Supersector Leader in the 2007 Dow Jones Sustainability Indexes
- Dow Jones Sustainability Index Again Recognizes Abbott
- Avastin approved in Europe for first-line treatment of patients with advanced lung cancer